The MET signaling pathway is often dysregulated in solid malignancies, including lung cancer, as a result of several mechanisms such as autocrine/paracrine stimulation, MET overexpression, genomic amplification, translocations, point mutations and alternative splicing (37). This evidence concerns the gene MET and lung carcinoma.